Could an Empathogen Like MDMA Help Prevent Sexual Offending?
Petros D. Petridis, Cristie Strongman, Rick Doblin
Psychedelics November 1, 2026 DOI: 10.1016/j.psyche.2026.100048 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Intervention | MDMA-assisted psychotherapy |
| Topics | MDMA |
| Key points | Argues that because no psychological treatment has been shown under rigorous controlled conditions to reduce sexual reoffending and most people arrested for a sexual offense have no prior conviction, prevention should target help-seeking people with paraphilic disorders. Proposes that MDMA-assisted psychotherapy, which in two phase 3 trials produced PTSD remission in 67% and 71% of participants versus 32% and 48% with placebo, could address shame and empathy deficits left unchanged by existing pharmacology, and outlines a proof-of-concept trial with safeguards. |
Abstract
ABSTRACT No psychological treatment for sexual offending has been shown, under rigorous controlled conditions, to reduce reoffending, and most people arrested for a sexual offense have no prior conviction. Prevention must begin upstream, with those who recognize their risk and seek help. The psychology of sexual offending overlaps with that of posttraumatic stress disorder (PTSD): shame, mistrust, and difficulty tolerating closeness, often rooted in abuse. MDMA-assisted psychotherapy may act on this psychology, lowering shame and fear while increasing closeness and emotional empathy. In two phase 3 trials, 67% and 71% of MDMA-treated participants no longer met PTSD criteria, versus 32% and 48% with placebo. Existing pharmacology for paraphilic disorders reduces deviant sexual interest and preoccupation but leaves empathy and self-regulation unchanged. Although MDMA may increase sexual desire, it delays orgasm and often impairs erectile and ejaculatory function, favoring closeness over culmination. We hypothesize that MDMA-assisted psychotherapy could address the gap left by existing pharmacology and reduce the risk of sexual offending in help-seeking people with paraphilic disorders. To test this hypothesis, we propose a small, ethically scrupulous proof-of-concept trial in voluntary, community-based participants, adapting the manualized protocol developed by the Multidisciplinary Association for Psychedelic Studies for PTSD. Safeguards should include co-therapist dyads, continuous recording with independent review, a touch protocol precluding sexual contact, deviant sexual interest as a prespecified safety outcome with a stopping rule, and sustained aftercare. Such a trial would be a first step toward prevention.